Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|RRx-001||RRx-001 is a nitric oxide donor that is activated by hypoxia, leading to increased oxygen level in tumor and sensitizes tumor to radiotherapy (PMID: 26164533, PMID: 32169409).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||RRx-001||Phase I||Actionable||In a Phase I trial, RRx-001 demonstrated safety and preliminary efficacy, resulted in partial response in 5% (1/21) and stable disease in 67% (14/21) of patients with advanced solid tumors (PMID: 26296952; NCT01359982).||26296952|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02215512||Phase I||RRx-001||Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases||Active, not recruiting|
|NCT02489903||Phase II||Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel||RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens||Active, not recruiting|
|NCT02452970||Phase II||RRx-001 Cisplatin + Gemcitabine||RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC)||Terminated|
|NCT03515538||Phase II||Cisplatin + RRx-001 RRx-001||Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers||Active, not recruiting|